CA2184712A1 - Traitement de la nephropathie diabetique a l'aide de valsartan - Google Patents

Traitement de la nephropathie diabetique a l'aide de valsartan

Info

Publication number
CA2184712A1
CA2184712A1 CA002184712A CA2184712A CA2184712A1 CA 2184712 A1 CA2184712 A1 CA 2184712A1 CA 002184712 A CA002184712 A CA 002184712A CA 2184712 A CA2184712 A CA 2184712A CA 2184712 A1 CA2184712 A1 CA 2184712A1
Authority
CA
Canada
Prior art keywords
glomerular
treatment
formula
compound
diabetic nephropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002184712A
Other languages
English (en)
Inventor
Marc De Gasparo
Nigel Levens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4195481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2184712(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2184712A1 publication Critical patent/CA2184712A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

On peut utiliser un antagoniste de l'angiotensine II de la formule (I) ainsi que les sels pharmacologiquement acceptables de celui-ci dans le traitement thérapeutique de la néphropathie diabétique.
CA002184712A 1994-03-17 1995-03-07 Traitement de la nephropathie diabetique a l'aide de valsartan Abandoned CA2184712A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH80094 1994-03-17
CH800/94-1 1994-03-17

Publications (1)

Publication Number Publication Date
CA2184712A1 true CA2184712A1 (fr) 1995-09-21

Family

ID=4195481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002184712A Abandoned CA2184712A1 (fr) 1994-03-17 1995-03-07 Traitement de la nephropathie diabetique a l'aide de valsartan

Country Status (12)

Country Link
EP (1) EP0750500A1 (fr)
JP (1) JPH09510225A (fr)
CN (1) CN1143908A (fr)
AU (1) AU1850695A (fr)
BR (1) BR9507086A (fr)
CA (1) CA2184712A1 (fr)
CZ (1) CZ268896A3 (fr)
FI (1) FI963611L (fr)
HU (1) HUT76542A (fr)
PL (1) PL316259A1 (fr)
SK (1) SK117996A3 (fr)
WO (1) WO1995024901A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0883401T3 (da) * 1996-02-29 2003-05-05 Novartis Ag AT1-receptorantagonist til stimulering af apoptose
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
WO1999012534A1 (fr) * 1997-09-10 1999-03-18 Ono Pharmaceutical Co., Ltd. Regulateurs des recepteurs actives par le proliferateur des peroxisomes
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
CN1304000C (zh) * 1998-12-23 2007-03-14 诺瓦提斯公司 缬沙坦在制备用于治疗肺癌的药物中的用途
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
NZ522953A (en) 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
AR032758A1 (es) 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1454625A1 (fr) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines pour le traitement des néphropaties diabétiques
WO2005046677A2 (fr) * 2003-11-14 2005-05-26 Novartis Ag Utilisation pharmaceutique supplementaire
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
WO2010104485A2 (fr) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Préparations de valsartan

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Also Published As

Publication number Publication date
MX9603999A (es) 1997-12-31
SK117996A3 (en) 1997-03-05
PL316259A1 (en) 1997-01-06
FI963611A7 (fi) 1996-09-13
JPH09510225A (ja) 1997-10-14
EP0750500A1 (fr) 1997-01-02
CN1143908A (zh) 1997-02-26
CZ268896A3 (en) 1997-03-12
BR9507086A (pt) 1997-09-16
AU1850695A (en) 1995-10-03
WO1995024901A1 (fr) 1995-09-21
HUT76542A (en) 1997-09-29
FI963611A0 (fi) 1996-09-13
FI963611L (fi) 1996-09-13
HU9602536D0 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
CA2184712A1 (fr) Traitement de la nephropathie diabetique a l'aide de valsartan
US20080027032A1 (en) Combinations comprising cox-2 inhibitors and aspirin
CN102091330A (zh) 含有缬沙坦和nep抑制剂的药物组合物
AU2026201003A1 (en) Crystal forms of a pyridazinone TRPC inhibitor
JP2008019273A (ja) 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
CN116199628B (zh) 固体[(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)氨基]乙酸
JP2014098016A (ja) 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用
RU2239454C2 (ru) Фармацевтическая композиция для предотвращения, лечения или ингибирования развития простой ретинопатии и препролиферирующей ретинопатии
US8455526B2 (en) Therapeutic use of imidazole-5-carboxylic acid derivatives
AU2011270133B2 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
WO1993015732A1 (fr) Traitement du glaucome
WO2014114627A1 (fr) Combinaisons avec de l'acide 2-aminoethanesulfonique
AU2020287549B2 (en) Therapeutic for gout or hyperuricemia
AU2021398258A1 (en) Intracellular atp enhancer
US7612082B2 (en) Prostaglandin EP4 antagonists
JP4276768B2 (ja) 単純網膜症・前増殖網膜症の予防・治療・進展抑制剤
US12552773B2 (en) Compound for specifically enhancing spatial coupling degree of TRPV4-KCa2.3 complex and use thereof
MXPA96003999A (en) Treatment of diabetic nephropathy with valsar
HK40085289B (zh) 固体[(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)氨基]乙酸
WO2010047369A1 (fr) Agent destiné au traitement de la néphropathie diabétique

Legal Events

Date Code Title Description
FZDE Discontinued